Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Merger Clears FTC; Estorra Rights To Be Divested

Executive Summary

Sanofi and Aventis will begin integrating management and operations following the Federal Trade Commission's July 28 approval of the merger of the two companies

You may also be interested in...



Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity

The House Energy and Commerce Committee's inquiries into Sanofi-Aventis' Ketek could be a jumping-off point for a wide-ranging congressional look into the integrity of clinical trials and oversight of companies involved in those trials

Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity

The House Energy and Commerce Committee's inquiries into Sanofi-Aventis' Ketek could be a jumping-off point for a wide-ranging congressional look into the integrity of clinical trials and oversight of companies involved in those trials

Sanofi-Aventis board vacancy

Aventis business development head and board member Thomas Hoefstatter announces plans to resign. He was expected to serve on the 18-member management committee of the newly merged company's board, and would have been one of 10 representatives of Aventis. Sanofi-Aventis says it is too soon to know how it will proceed with the management and board vacancy, but that it will meet its deadline for putting the new operational structure in place by Jan. 1 (1"The Pink Sheet" Aug. 2, 2004, p. 3)...

Related Content

Topics

UsernamePublicRestriction

Register

PS044443

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel